论文部分内容阅读
目的:研究血液灌流与动脉化疗栓塞(TACE)联合应用治疗肝癌的疗效。方法:(1)对象:灌流组17例肝癌患者,采用TACE联合NK-107树脂血液灌流进行治疗。对照组11例肝癌患者,采用单纯TACE治疗。(2)观察项目:阿霉素血药浓度、临床症状体征的变化、血常规、心肌酶、肝肾功能、心电图、超声、CT、甲胎蛋白等。结果:灌流组的阿霉素给药剂量虽然为对照组的1.5倍,但血药浓度低于对照组,于第3、14天时降低程度具有统计学意义。血象、心肌酶、肝肾功能与给药前比较均无明显改变。临床表现:灌流组在发热、胃肠道反应、脱发、心脏副作用等方面均较对照组为低。结论:血液灌流配合TACE可以较好吸附逸出至肝外化疗药物,有效降低毒副作用,可提高患者对介入治疗的耐受性。
Objective: To study the curative effect of hemoperfusion combined with arterial chemoembolization (TACE) in the treatment of liver cancer. Methods: (1) Subjects: 17 patients with hepatocellular carcinoma in perfusion group were treated with TACE and NK-107 resin hemoperfusion. Control group of 11 patients with liver cancer, using simple TACE treatment. (2) observation items: doxorubicin blood concentration, changes in clinical symptoms and signs, blood, myocardial enzymes, liver and kidney function, electrocardiogram, ultrasound, CT, a fetoprotein. Results: Although the dose of doxorubicin in the perfused group was 1.5 times that of the control group, the plasma concentration was lower than that of the control group, and the decrease was statistically significant on the 3rd and 14th days. Blood, myocardial enzymes, liver and kidney function compared with before administration no significant change. Clinical manifestations: perfusion group in the fever, gastrointestinal reactions, hair loss, heart and other side effects were lower than the control group. Conclusion: Hemoperfusion combined with TACE can better adsorb chemotherapeutic drugs that escape to the outside of the liver, effectively reducing the side effects and improving the patient’s tolerance to interventional therapy.